Psyros Diagnostics Ltd. Awarded £400K Innovate UK Smart Award to accelerate development of their ground-breaking ultra-sensitive IVD technology

30 Sept. 2019, UK

Coronary heart disease is one of the leading causes of death within the UK. Every day over 2500 patients present at A&E departments across the UK with chest pain, indicative of a suspected heart attack. Of these, only 20% will have a confirmed heart attack. Diagnosis often takes several hours after arriving at A&E while healthcare professionals wait for test results to be processed by the hospital laboratory. Faster identification of these patients will save lives and improve the outcomes for patients, ensuring they receive rapid treatment. Timely discharge of the remaining 80%, who are not suffering a heart attack, minimises unnecessary hospital admissions and costs to the NHS.

During a heart attack, a protein called troponin (Tn) is released into the bloodstream from the damaged heart muscle. Psyros are developing a game-changing point-of-care technology able to measure the extremely low levels of Tn needed by clinicians to make critical rule in/rule out care decisions as quickly as possible. Our highly innovative and patent-pending system is designed to detect these ultra-low Tn levels from a small drop of blood taken from the finger by measuring the individual Tn molecules, giving accurate and actionable results within 10 mins. We have already shown feasibility of our disruptive approach through our successful Innovate UK precision medicine feasibility award project. This project builds on the success of that feasibility work by demonstrating the required functional clinical performance.
Psyros Diagnostics Ltd.

Psyros Diagnostics was formed in 2018 by a team of experienced in-vitro diagnostics developers that acquired key assets from the Novartis Near-Patient Testing Unit . Psyros recognise the unmet need for rapid and ultra-sensitive testing at the point of need to improve health outcomes and quality of life for patients. The team have a proven track record in clinical diagnostics development, from initial concept phase through to CE marking in both a start-up and a multinational healthcare company environment. Psyros are rapidly developing their system to address the unmet clinical need for patients for Acute Cardiac and other applications requiring ultra-sensitive testing.

Innovate UK
Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. Innovate UK drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.
For further information, please contact: enquiries@psyrosdiagnostics.com

Website: www.psyrosdiagnostics.com


Cytox raises £2.6m led by Catapult Ventures to launch predictive testing service for Alzheimer’s disease

Investment will help commercialize Cytox’s services for testing for Alzheimer’s disease and grow C...

Read More >

Genedrive Receives NHS Grant

The UK NHS National Institute for Health Research in June 2018 have offered Professor Bill Newman an...

Read More >

Evaluation studies confirm improved oncology patient pathways through HORIBA Medical’s new POC haematology analyser

Yumizen H500 full blood count analyser demonstrates exceptional correlation with larger laboratory-b...

Read More >

EKF introduces mobile data management solution for the DiaSpect Tm POC hemoglobin analyzer

Cardiff, UK – 13th November 2017 – EKF Diagnostics, the global in vitro diagnostics company, today...

Read More >

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated I...

Read More >

OGT further expands global direct sales and support into Asia-Pacific region

Following successful European rollout, more customers to benefit from enhanced local sales and suppo...

Read More >